{
    "id": 26086,
    "fullName": "MET V1155L",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MET V1155L lies within the protein kinase domain of the Met protein (UniProt.org). V1155L is associated with resistance to some Met inhibitors in the context of TPR-MET (PMID: 21697284), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "V1155L",
    "createDate": "02/28/2017",
    "updateDate": "03/14/2020",
    "referenceTranscriptCoordinates": {
        "id": 144937,
        "transcript": "NM_000245",
        "gDna": "chr7:g.116778898G>C",
        "cDna": "c.3463G>C",
        "protein": "p.V1155L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a TPR-MET fusion harboring MET V1155L demonstrated resistance to inhibition by NVP-BVU972 in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27248,
                "profileName": "TPR - MET MET V1155L"
            },
            "therapy": {
                "id": 5378,
                "therapyName": "NVP-BVU972",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21106,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited proliferation of a transformed human cell line expressing a TPR-MET fusion bearing MET V1155L in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 27248,
                "profileName": "TPR - MET MET V1155L"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27247,
            "profileName": "MET V1155L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27248,
            "profileName": "TPR - MET MET V1155L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144937,
            "transcript": "NM_000245",
            "gDna": "chr7:g.116778898G>C",
            "cDna": "c.3463G>C",
            "protein": "p.V1155L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}